The Role of Data Analytics in Clinical Trial Design and Analysis

Recently updated

What function does data analysis play in clinical trials? Can R and other technologies be used to improve clinical trial data analysis? Is it possible to use big data analysis in clinical trials? Experts would undoubtedly answer yes to all of these questions.

Clinical trials have changed dramatically in the recent decade, with significant new advances in immunotherapy, stem cell research, genomics, and cancer therapy, to name a few. Simultaneously, there has been a shift in the implementation of clinical trials as well as the process of discovering and producing required medications. 

Researchers acquire faster insights through the review of databases of real-world patient information and the production of synthetic control arms, to name a few instances of the expanding demand for clinical trial data analysis.

In this instance, they can also assess medication performance after regulatory approval. This has reduced the expense and time associated with studies, while also reducing the total burden on patients and allowing for shorter medication go-to-market timetables. 

What is driving data analysis in clinical trials? 

AI (artificial intelligence) and ML (machine learning) are driving clinical trial data analysis, allowing for the gathering, analysis, and creation of insights from huge volumes of real-time data at scale, which is far quicker than manual techniques.

The analysis and processing of medical imaging data for clinical trials, as well as data from other sources, is allowing process innovation while also aiding the discovery processes in terms of speeding up trials, go-to-market methods, and launches. 

Data volumes have skyrocketed in recent years, thanks to greater wearable usage, genomic and genetic understanding of individuals, proteomic and metabolomic profiles, and complete clinical histories obtained from electronic health records.

According to reports, the global healthcare business generates 30% of the world's data volumes. The CAGR (compound annual growth rate) for healthcare data will also reach 36% by 2025. From 2016 to 2020, the volume of patient data in healthcare systems has increased by a stunning 500%. 

Data analysis in clinical trials- What else should you note? 

Here are a few factors that are worth noting: 

AI-based solutions have been able to use massive amounts of data while curating and storing it in non-standard forms. Machine learning enables the detection of data patterns in the absence of any prior preconceptions. 

New AI technologies are likely to have a significant impact on medication research and clinical trials. According to Morgan Stanley Research, the use of ML and AI might result in 50 additional novel cures over the next ten years, turning into a market worth more than $50 billion. ML is already being used in conjunction with statistical analysis to glean insights from massive real-world data warehouses and clinical histories. 

Clinical trial design software and data modeling approaches are already being employed extensively, from discovering laboratory indicators for forecasting the possibility of complicated syndromes in patients of various categories to researching and comprehending clinical risk aspects. 

Life sciences organizations are utilizing AI technologies to ensure that clinical trials generate regulatory-quality data, as well as classifying and sorting information entry issues, inconsistencies, outliers, and other misreported but adverse effects in order to expedite drug approval procedures. 

• Synthetic control arm development 

When considering the creation of synthetic control arms, the relevance of data analysis in clinical trials becomes further clearer. Clinical drug research and testing might be accelerated while improving success rates and clinical trial designs.

Synthetic control arms may aid in overcoming patient classification issues and shortening the time necessary for medical therapy development. It may also improve patient recruitment by alleviating worries about receiving placebos and allowing for better administration of varied and large-scale trials. 

Synthetic control arms use both historical clinical trials and real-world data to mimic patient control groups, eliminating the need for patients to receive placebo treatments that may be harmful to their health. It may have a detrimental influence on patient outcomes and trial enrollment.

The strategy may be more effective for uncommon diseases with smaller patient populations and shorter lifespans due to the disease's aggressive nature. Using such technologies for clinical trials and bringing them closer to end-patients may considerably reduce the overall hassles of going to research locations/sites, as well as the issue of consistent testing. 

• ML and AI for better discovery of drugs

For physicians, ML and AI may enable faster analysis of data sets obtained earlier and at a faster rate, resulting in improved reliability and efficiency. The incorporation of artificial intelligence in clinical trial design for synthetic control arms into conventional research will open up new avenues for medication development transformation. 

As the number of data sources increases, such as health apps, personal wearables and other devices, electronic medical records, and other patient data, these may become the safest and quickest mechanisms for tapping real-world data for better research into ailments with large patient populations.

Researchers may attain larger, more homogeneous patient groups while still gaining critical insights. Here are some other items to consider: 

ML and AI tools may aid in the discovery of crucial insights that would otherwise take a large number of hours for humans. They can produce findings in a matter of minutes. 

Larger pharmaceutical companies may have several active studies with multiple databases. There is a greater requirement for efficient data analysis and management when there are several data points. Otherwise, data mismanagement might lead to costly blunders. 

These tools may be used by researchers to quickly discover crucial trends and potential trial-related issues in real-time. 

In Summation

Data analysis allows for the prediction of clinical trial outcomes for novel drugs. All stakeholders benefit from faster and more precise results/predictions, as well as superior risk and reward estimates. 

Researchers may construct clinical trials more successfully with improved visibility into drug development risks, broadening patient selection criteria and quickly sorting through numerous aspects at the same time. 

Data analytics is allowing for better decision-making throughout the drug development process, while also improving overall clinical trial efficiency through predictive modeling, discovering new possible candidate molecules for effective medication development with more confidence. 

Companies may give real-time reactions to clinical data insights via automation and big data, while also generating more efficient trials and significantly reducing trial duration. 

Clinical trial outcomes are important performance indicators, at least in the eyes of firms and investors. They are also the start of cooperation between patients, groups, and the broader healthcare industry. As a result of the aforementioned factors, there is an obvious demand for big data analysis in clinical trials.